AJUNTAMENT D'ALCOI
Website
Generalitat Valenciana
Website
Ayuntamiento de Valencia
Website
Cicloplast
Website
Ayuntamiento de Onil
Website
Anarpla
Website
Ayuntamiento de Mislata
Website
nlWA, North London Waste Authority
Website
Ayuntamiento de Salinas
Website
Zicla
Website
Fondazione Ecosistemi
Website
PEFC
Website
ALQUIENVAS
Website
DIPUTACI� DE VAL�NCIA
Website
AYUNTAMIENTO DE REQUENA
Website
UNIVERSIDAD DE ZARAGOZA
Website
OBSERVATORIO CONTRATACIÓN PÚBLICA
Website
AYUNTAMIENTO DE PAIPORTA
Website
AYUNTAMIENTO DE CUENCA
Website
BERL� S.A.
Website
CM PLASTIK
Website
TRANSFORMADORES INDUSTRIALES ECOL�GICOS
INDUSTRIAS AGAPITO
Website
RUBI KANGURO
Website
If you want to support our LIFE project as a STAKEHOLDER, please contact with us: life-future-project@aimplas.es
In this section, you can access to the latest technical information related to the FUTURE project topic.
Prior administration of vitamin K<sub>2</sub> improves the therapeutic effects of zoledronic acid in ovariectomized rats by antagonizing zoledronic acid-induced inhibition of osteoblasts proliferation and mineralization
Zoledronic acid (ZA) exerts complex influence on bone by suppressing bone resorption, mostly due to the direct osteoclasts inhibition and uncertain influence on osteoblasts. Vitamin K2 (VK2, Menaquinone-4) as an anabolic agent stimulates bone formation via anti-apoptosis in osteoblasts and mild osteoclasts inhibition. Based on these knowledge, the therapeutic effect of the combined or sequential therapy of VK2 and ZA depends on the influence on the osteoblasts, since both cases exert similar inhibitory effect on osteoclasts. In a series of in vitro studies, we confirmed the protective effect of VK2 in osteoblasts culture, especially when followed by exposure to ZA, and the proliferation and mineralization inhibition induced by ZA towards osteoblasts. For mechanism study, expression of bcl-2/bax, Runx2 and Sost in cells were examined. For in vivo studies, an osteoporosis animal model was established in rats via ovariectomy (OVX) and subjected to sequential treatment, namely VK2 followed by ZA. Bone mineral density (BMD) was measured by Dual energy X-ray absorptionmetry (DEXA), morphology and mechanical parameters by micro-computed tomography (micro-CT), mechanical strength by an electro-hydraulic fatigue-testing machine. The bone calcium, hydroxyproline content, blood lipids were evaluated using microplate technique, and the bone surface turnover was evaluated using the fluorescence in corporation method. It was found that VK2 pretreatment partially prevented the inhibition of bone formation caused by ZA, which was reflected by indices like BMD, bone calcium content and bone strength. The underling mechanisms for protection of VK2 pretreatment, mainly demonstrated via in vitro studies, included inhibiting apoptosis and depressing Sost expression in osteoblasts, which in turn improved the osteoporosis therapeutic effects of ZA. These findings suggested that pretreatment with VK2 before ZA therapy might serve a new long-term therapy protocol for osteoporosis.
» Author: Bin Zhao, Wenqian Zhao, Yiqiang Wang, Zhao Zhao, Changfeng Zhao, Shue Wang, Chunzheng Gao
» Reference: https://doi.org/10.1371/journal.pone.0202269
» Publication Date: 20/08/2018
C/ Gustave Eiffel, 4
(València Parc Tecnològic) - 46980
PATERNA (Valencia) - SPAIN
(+34) 96 136 60 40
Project Management department - Sustainability and Industrial Recovery
life-future-project@aimplas.es